trans-1-chloro-3-3-3-trifluoropropene and Heart-Diseases

Trans-1233zd was developed as a refrigerant and propellant in consumer products; its toxicity has been studied extensively. The scope of this assessment is to apply the confirmed NOAEC to conduct Benchmark Dose Modeling (BMD) and determine the Point of Departure (POD). In a previously published 13-week inhalation study, a NOAEC was identified at 4000 ppm. Due to uncertainty concerning the cardiac lesion, an external pathology peer review of heart tissues was undertaken using published best practices and consistent nomenclature and diagnostic criteria. The cardiac lesion observed at 4000 ppm was considered to be spontaneous based on lesion location and microscopic features. BMD was applied to derive the BMDL

Topics: Administration, Inhalation; Animals; Benchmarking; Chlorofluorocarbons; Chlorofluorocarbons, Methane; Dose-Response Relationship, Drug; Environmental Exposure; Female; Heart Diseases; Inhalation Exposure; Male; Models, Biological; No-Observed-Adverse-Effect Level; Rats; Rats, Sprague-Dawley; Risk Assessment